公开(公告)号：US20190031780A1

公开(公告)日：2019-01-31

申请号：US16073349

申请日：2017-01-27

申请人： Siamab Therapeutics, Inc. ,  The General Hospital Corporation

发明人： David A. Eavarone ,  Jeffrey Behrens ,  Jillian M. Prendergast ,  Bo R. Rueda ,  Rosemary Foster ,  Kristen D. Starbuck

IPC分类号： C07K16/44 ,  A61K31/337 ,  A61K31/555 ,  A61K39/395 ,  A61K47/68 ,  G01N33/574 ,  A61P35/00

摘要： Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.

公开(公告)号：US20170305950A1

公开(公告)日：2017-10-26

申请号：US15518179

申请日：2015-10-09

申请人： SIAMAB THERAPEUTICS, INC.

发明人： Ana Paula Galvao da Silva ,  Mai Zhang ,  Darius Ghaderi ,  Julie DeSander ,  Jeffrey Behrens ,  Jillian M. Prendergast

IPC分类号： C07H15/04 ,  G01N33/574 ,  C40B40/12 ,  G01N33/68

CPC分类号： C07H15/04 ,  C40B40/12 ,  G01N33/57484 ,  G01N33/6854 ,  G01N2400/12 ,  G01N2400/38

摘要： The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.

公开(公告)号：US20170306046A1

公开(公告)日：2017-10-26

申请号：US15526593

申请日：2015-11-12

申请人： SIAMAB THERAPEUTICS, INC.

发明人： Ana Paula Galvao daSilva ,  Darius Ghaderi ,  Mai Zhang ,  Kristan Meetze ,  Julie DeSander ,  Jeffrey Behrens ,  David A. Eavarone ,  Jillian M. Prendergast ,  Alexey Alexandrovich Lugovskoy

IPC分类号： C07K16/30 ,  C07K16/00 ,  G01N33/574

CPC分类号： G01N33/57492 ,  A61K47/6817 ,  A61K47/6851 ,  C07K16/005 ,  C07K16/3076 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

摘要： The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.

公开(公告)号：US20180327509A1

公开(公告)日：2018-11-15

申请号：US15775410

申请日：2016-11-10

申请人： SIAMAB THERAPEUTICS, INC.

发明人： David A. Eavarone ,  Jillian M. Prendergast ,  Jeffrey Behrens ,  Alexey Alexandrovich Lugovskoy ,  Daniel T. Dransfield

IPC分类号： C07K16/30 ,  A61K47/68

CPC分类号： C07K16/3084 ,  A61K47/6803 ,  A61K47/6817 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/572 ,  C07K16/3092 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/77 ,  C07K2317/92

摘要： The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include humanized antibodies, derivatives and fragments thereof as well as related compositions and kits. Methods of using glycan-interacting antibodies for treatment and diagnosis are included.